Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,666 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolic Complications Clear all

Conditions: End Stage Renal Disease, Hyperphosphatemia, Chronic Inflammation
Interventions: Ferric Citrate; Drug
Lead sponsor: Winthrop University Hospital; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Obesity, Type 2 Diabetes, Chronic Kidney Disease (CKD)
Interventions: Social Cognitive Theory, Monitoring; Behavioral · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years and older
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19, Long COVID
Interventions: MouthLabTM; Device
Lead sponsor: Edith Nourse Rogers Memorial Veterans Hospital; Federal
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Bedford, Massachusetts

Conditions: Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia
Interventions: SPR001; Drug
Lead sponsor: Spruce Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 9
States / cities: Orange, California • San Diego, California • Melbourne, Florida + 6 more

Conditions: Congenital Adrenal Hyperplasia
Interventions: Chronocort; Drug
Lead sponsor: Immedica Pharma AB; Industry
Eligibility: 16 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 11
States / cities: Los Angeles, California • Orange, California • Jacksonville, Florida + 8 more

Conditions: Obstructive Sleep Apnea, Pregnancy, Obesity, Preeclampsia, Sleep
Interventions: Positive Airway Pressure, Nasal Dilator Strips; Device · Other
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Diabetic Retinopathy
Interventions: Ophthalmic Telemedicine; Procedure
Lead sponsor: Legacy Health System; Other
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Wichita, Kansas • Pendleton, Oregon

Conditions: Hyperuricemia, Gout, Chronic Kidney Diseases
Interventions: ALLN-346, Placebo; Drug
Lead sponsor: Allena Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 17
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Sheffield, Alabama + 12 more

Conditions: Metabolic Acidosis
Interventions: TRC101, Placebo; Drug
Lead sponsor: Tricida, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Phoenix, Arizona • Los Angeles, California • Hialeah, Florida + 4 more

Conditions: Diabetes Mellitus, Diabetic Neuropathy
Interventions: Anodyne Therapy System; Device
Lead sponsor: Scott and White Hospital & Clinic; Other
Eligibility: 25 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Gestational Diabetes
Interventions: Shared decision-making with pharmacists; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 20
States / cities: Burbank, California • Los Angeles, California • Pacific Palisades, California + 2 more

Conditions: Obesity, Overactive Bladder, Incontinence
Interventions: Trospium Chloride, Extended Release (XR), placebo; Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: La Mesa, California

Conditions: Diabetes, Gestational
Interventions: Dexcom G6; Device
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Congenital Adrenal Hyperplasia
Interventions: Chronocort, Cortef, Placebo; Drug · Other
Lead sponsor: Neurocrine UK Limited; Industry
Eligibility: 16 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 11
States / cities: Los Angeles, California • Orange, California • Jacksonville, Florida + 8 more

Conditions: Diabetic Foot Ulcer
Interventions: gentamicin-collagen sponge and levofloxacin, Levofloxacin only; Drug
Lead sponsor: Innocoll; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Lakeland, Florida

Conditions: Diabetes Mellitus, Metabolic Syndrome, Obesity, Hypertension,Essential, Hyperlipidemias, Cardiovascular Diseases, Kidney Disease, Chronic
Interventions: Lifestyle Medicine Program, Medically Tailored Groceries; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Drug Use, Alcohol Use, Congestive Heart Failure, Pneumonia, Acute Myocardial Infarction, Diabetes Mellitus, Chronic Obstructive Pulmonary Disease, End-Stage Renal Disease
Interventions: Specialized Community Disease Management, Treatment As Usual; Behavioral
Lead sponsor: Treatment Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus
Interventions: Effect of Pulsatile IV insulin on diabetic pt blood markers, Effect of Pulsatile IV Insulin on blood markers; Procedure
Lead sponsor: Florida Atlantic University; Other
Eligibility: 21 Years to 85 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Hypertriglyceridemia
Interventions: Liposyn III 20% (lipid infusion), Intralipid 20% (lipid infusion); Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 2 Days to 10 Days
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Thromboelastography, Coagulation; Fetus or Newborn, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes, Gestational
Interventions: Laboratory clotting studies; Other
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 0 Hours to 2 Hours
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Endometrial Cancer
Interventions: Baseline Measures, Strength-Training, Mid-point Measures, Post-Study Measures; Other · Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 74 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Polycystic Ovary Syndrome (PCOS), Menstrual Irregularity, Overweight and Obesity
Interventions: Not listed
Lead sponsor: Cornell University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Polycystic Ovary Syndrome, Anovulation, Hyperandrogenism, Insulin Resistance, Glucose Intolerance, Metabolic Complication
Interventions: Placebo, Inositol; Other · Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Hershey, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Electrolyte Imbalance, Hyponatremia, Hypernatremia
Interventions: V2R (Vasopressin 2 receptor); Drug
Lead sponsor: Oakland University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Rochester, Michigan

Search by objective public record fields.

A Study of Ferric Citrate to Improve Inflammation and Lipid Levels

Lifestyle Management of CKD in Obese Diabetic Patients

Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)

Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia

Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia

Positive Airway Pressure, Sleep Apnea, and the Placenta (PAP-SAP)

The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy

Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease

Long-term Safety Extension to Study TRCA-301

Anodyne Therapy in Diabetic Sensory Neuropathy

Shared Decision Making in Diabetes Prevention for Women With a History of GDM

Trospium Chloride XR in Obese Female Patients With Overactive Bladder

Continuous Glucose Monitoring for Various Degrees of Glucose Intolerance

Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers

Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome

Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions

Effect of Pulsatile IV Insulin on Circulating Risk Markers of Vascular and Metabolic Complications in Pts With Diabetes

Fat Tolerance From Lipid Emulsion Infusion Packaged in Glass or Plastic

Thromboelastographic Profile in Healthy Newborns and Infants of Diabetic Mothers Using TEG6s

Telehealth-Based Resistance Training Intervention for Endometrial Cancer Survivors

Ovarian Ultrasonography for the Clinical Evaluation of Polycystic Ovary Syndrome

Inositol Supplementation to Treat PCOS (INSUPP-PCOS)

V2 Receptor Effects on Fluid Regulation and Performance